Atezolizumab (atezo) vs chemotherapy (chemo) in platinum-treated locally
   advanced or metastatic urothelial carcinoma (mUC): immune biomarkers,
   tumor mutational burden (TMB) and clinical outcomes from the Phase III
   IMvigor211 study

Document type:: Meeting Abstract
Author(s):: von Amsberg, G.; Powles, T.; Loriot, Y.; Ravaud, A.; Vogelzang, N. J.; Duran, I.; Retz, M.; De Giorgi, U.; Oudard, S.; Bamias, A.; Koeppen, H.; Leng, N.; Kadel, E. E.; Hegde, P. S.; Cui, N.; Shen, X.; Green, M.; Banchereau, R.; Mariathasan, S.; van der Heijden, M. S.
Title:: Atezolizumab (atezo) vs chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): immune biomarkers, tumor mutational burden (TMB) and clinical outcomes from the Phase III IMvigor211 study
Journal title abbreviation:: Oncology Research and Treatment
Year:: 2018
Journal volume:: 41
Pages contribution:: 325-326
Print-ISSN:: 2296-5270
TUM Institution:: Urologische Klinik und Poliklinik
BibTeX

Occurrences: